

2/9/2018

Conflict of Interest Disclosures Blood Advances

00000429652	Geoff Hill, MD	Associate Editor	Last Confirmed Date: 07/13/2016
--------------------	-----------------------	-------------------------	--

Company:	Relationship:	Additional Information	End Date
Roche	Research Funding	Clinical trial support	07/01/2018

00000430052	Leslie Kean, MD, PhD	Associate Editor	Last Confirmed Date:
--------------------	-----------------------------	-------------------------	-----------------------------

Company:	Relationship:	Additional Information	End Date
-----------------	----------------------	-------------------------------	-----------------

000001006795	Claudia Lengerke, MD	Associate Editor	Last Confirmed Date: 01/15/2018
---------------------	-----------------------------	-------------------------	--

Company:	Relationship:	Additional Information	End Date
	Employment	employment as physician-scientist in the Hematology/Oncology Department	01/01/2038
	Research Funding	Max Eder Junior Group Leader Program	
	Research Funding	project leader	09/01/2018

Conflict of Interest Disclosures Blood Advances

00000424143	Nikhil C. Munshi, MD	Associate Editor	Last Confirmed Date: 07/10/2016
Company:	Relationship:	Additional Information	End Date
Amgen	Consultancy		01/01/2018
Celgene	Consultancy		01/01/2018
Celgene	Consultancy		
Celgene	Honoraria		
Celgene	Membership on a Board or Advisory Committee		
Celgene	Speakers Bureau		
Janssen	Consultancy		01/01/2018
Janssen Pharmaceutical	Consultancy		
Merck	Consultancy		01/01/2018
Millennium	Honoraria		
Millennium	Speakers Bureau		
Novartis	Honoraria		
Novartis	Speakers Bureau		
Oncoprep	Consultancy		01/01/2019
Oncoprep	Consultancy		
Oncoprep	Equity Ownership		01/01/2036
Oncoprep	Equity Ownership		
Oncoprep	Membership on a Board or Advisory Committee		01/01/2019
Oncoprep	Membership on a Board or Advisory Committee		
Oncoprep	Patents & Royalties		01/01/2019
Onyx	Membership on a Board or Advisory Committee		
Takeda	Consultancy		01/01/2018

Conflict of Interest Disclosures Blood Advances

000000124518	Robert Negrin, MD	Editor	Last Confirmed Date: 02/01/2018
---------------------	--------------------------	---------------	--

Company:	Relationship:	Additional Information	End Date
	Equity Ownership		01/01/2035
Amgen	Consultancy		01/01/2020
BioEclipse Therapeutics	Equity Ownership		01/01/2038
BioEclipse Therapeutics	Membership on a Board or Advisory Committee		01/01/2038
Cell Source	Consultancy		01/01/2036
Cell Source	Equity Ownership		01/01/2036
Formula	Equity Ownership		
Formula	Membership on a Board or Advisory Committee		
Jazz	Consultancy		
Magenta	Equity Ownership		
Magenta	Membership on a Board or Advisory Committee		
UpToDate	Consultancy		01/01/2035

000000426024	Julie A. Panepinto, MD, MSPH	Associate Editor	Last Confirmed Date: 01/31/2018
---------------------	-------------------------------------	-------------------------	--

Company:	Relationship:	Additional Information	End Date
	Research Funding	National Heart, Lung and Blood Institute	
HRSA	Research Funding	I am a co-investigator (site PI) receiving research funding from this government agency.	09/30/2020
NIAMS	Research Funding	I have NIH research funding from this institute.	08/31/2019

Conflict of Interest Disclosures Blood Advances

00000122821	Margaret V. Ragni, MD, MPH	Associate Editor	Last Confirmed Date: 01/28/2018
Company:	Relationship:	Additional Information	End Date
Anylam	Honoraria	This was to give talk for an online Medical Program for Investors.	01/01/2035
Anylam	Research Funding	This is for participation in phase 1, 2, 3 studies of novel bypass, siRNA-AT3, fitusiran.	01/01/2035
American Academy of CME	Honoraria	Moderator, Speaker for ASH Satellite Symposium: Clinical Challenges in von Willebrand Disease Management: Talk: "Managing the Bleeding Patient with VWD in the Emergency Department," San Diego CA, Dec 2, 2016	01/01/2036
American Thrombosis Research Network ATHN	Membership on a Board or Advisory Committee	I have served on an advisory committee and a grants review committee.	
American Thrombosis Research Network ATHN	Research Funding	This supports clinical outcomes data collection, and support for clinical trials and observational studies in patients with bleeding disorders.	
Baxalta/ Baxter Healthcare	Membership on a Board or Advisory Committee	Advisory Board for GI/Liver Disease (2010) Advisory Board for rVWF in Women's Health (2015-)	01/01/2035
Baxalta/ Baxter Healthcare	Research Funding		01/01/2035
Baxter Bioscience	Honoraria		

Conflict of Interest Disclosures Blood Advances

Baxter Bioscience	Research Funding	<p>1. Research studies involving recombinant VWF in Von Willebrand disease. This provides funds to study dendritic cells in inducing tolerance in hemophilia A mice with inhibitors.</p> <p>2. Dendritic cell vaccine in tolerance induction in hemophilia A mouse, Co-PI</p> <p>3. Recombinant VWF PK and Safety study, Co-investigator</p> <p>4. FVIIa BI Dose Escalation Study, Co-investigator</p>	
Bayer	Consultancy		
Bayer	Consultancy	Served on panel to research and discuss current problems in hemophilia.	01/01/2018
Bayer	Research Funding		
Bayer	Research Funding	Research study of novel bypass agent	01/01/2021
Biogen	Research Funding	<p>1. Research studies on long acting factor VIII and factor IX in hemophilia subjects.</p> <p>2. Long-acting Factor IX, PK and safety Phase I/II study, Co-investigator</p> <p>3. Long-acting Factor IX for phase III efficacy, Co-investigator</p> <p>4. Long-acting Factor VIII, PK and Safety Phase I/II study, Co-investigator</p> <p>5. Long-acting Factor VIII for phase III efficacy, Co-investigator</p>	01/01/2038
Biogen Idec	Consultancy		
Biogen Idec	Research Funding		
Biogen Idec: Consultantancy	Consultancy	I spoke as a hematologist to an investor's meeting regarding medical problems and potential benefits of a long-lasting clotting factors.	
Biogen Idec: Consultantancy	Membership on a Board or Advisory Committee	I serve as a medical consultant to Biogen on a medical advisory board.	

Conflict of Interest Disclosures Blood Advances

Biogen/Bioverativ	Research Funding	Investigator-Initiated Research: To use FVIII Fc for ITI (HIRE trial) Research study of long-acting FVIII Fc-VWF-XTEN	01/01/2035
Biomarin	Consultancy	This was for planning for a gene therapy trial.	01/01/2035
Biomarin	Research Funding	This is a research trial of BMN gene therapy for hemophilia A.	
Bristol Myers Squibb	Research Funding		
Centers for Disease Control	Research Funding	Hemophilia UDC, Clinical Outcomes, Co-investigator (Region III)	
Chiron (formerly Novartis)	Research Funding	Long-term followup for retroviral VIII gene transfer in hemophilia, Co-investigator	01/01/2034
CSL Behring	Research Funding		01/01/2035
CSL Behring	Research Funding	1.Subcontract (UNC) Deep venous thrombosis in Hemophilia, Co-investigator 2.FVIIa-FP Phase III Trial in Hemophilia Inhibitor Patients, Co-Investigator	
Dimension Therapeutics	Research Funding	This is for hemophilia gene therapy study.	01/01/2035
Foundation for Women and Girls with Blood Disorders	Membership on a Board or Advisory Committee	Foundation for Women and Girls with Blood Disorders, Medical Advisory Board (2010-)	
Genentech Roche	Research Funding	This is for participation in a research trial of bispecific FVIII monoclonal antibody.	01/01/2035
Haemophilia	Membership on a Board or Advisory Committee	Haemophilia, Editorial Board Member	
Hematologist (ASH)	Membership on a Board or Advisory Committee	The Hematologist (ASH) Editorial Board 2011-	
Hemostasis Thrombosis Research Society	Membership on a Board or Advisory Committee	Co-Chair Research Committee Board of Directors	

Conflict of Interest Disclosures Blood Advances

Institute for Cost Effectiveness Research (ICER)	Consultancy	Participation in review and public discussion of a white paper on cost-effectiveness of novel bypass Hemlibra (emicizumab) in hemophilia inhibitor patients.	
Johns Hopkins CME	Honoraria	Thrombosis Haemostasis Society of North American (THSNA) Symposium Speaker: "Improving Outcomes in Hemophilia A: Extended Half-life Factor VIII," Chicago IL, April 14, 2016.	01/01/2036
Journal of Rare Disorders	Membership on a Board or Advisory Committee	I serve on the editorial board of The Journal of Rare Disorders.	
Journal THrombosis Haemostasis	Membership on a Board or Advisory Committee	I serve on the JTH Editorial Advisory Board.	
MCHB HHS Region III Fed HTC's	Research Funding	Hemophilia Diagnostic and Treatment Center, Co-investigator	
Medscape, Inc.	Honoraria	This was for speaking at ASH SuperFriday Symposium on Extended Half life Products for hemophilia.	01/01/2035
Medscape, Inc.	Membership on a Board or Advisory Committee	This was for planning Educational programs on hemophilia for various venues.	01/01/2035
National Hemophilia Foundation	Membership on a Board or Advisory Committee	1. NHF, Member MASAC 2. NHF, Women's Health Initiative, Member (2009-)	
NHLBI	Membership on a Board or Advisory Committee	1. NHLBI HT Study Section 2007-2011, Member, Ad Hoc Member 2013 2. NHLBI State of the Science: Co-Chair Hemophli & VWD Subcommittee 3. ASH/NHLBI Worskhop on Recruitment, Retention of Hematologists 4. NHLBI Working Goup on HIV Research in Heart, Blood, Lung Diseases, 2012	

Conflict of Interest Disclosures Blood Advances

NHLBI	Research Funding	<p>1. (Subcontract St. Jude's Hospital) AAV-8 IX Gene Trial in Hemophilia, Co-investigator</p> <p>2. (B2B) Mechanism of Hemolysis Activation in SCD, Co-investigator, 2009-2012</p> <p>3. (NIAID) Solid Organ Transplant in HIV+ Recipients, Co-investigator 2003-2012</p> <p>4. (PPG) Molecular and Clinical von Willebrand Disease, Co-investigator</p> <p>5. (T35) T35 Training Students in Biomedical Research, Principal Investigator</p> <p>6. Transfusion Medicine Hemostasis Network, Co-investigator, 2002-2012</p> <p>7. (K23) Multicenter Trial</p>	
NovoNordisk	Research Funding		
OPKO Biologics	Research Funding	Clinical Trial funding: Phase 1/2 Study to Assess Safety and Pharmacokinetics of Long Acting VIIa in Hemophilia A and B.	01/01/2036
PA Dept of Health	Research Funding	State Hemophilia Program, Principal Investigator	
Pfizer	Research Funding	FVIIa Variant in Hemophilia Inhibitor Patients	
Postgraduate Institute for Medicine	Honoraria	Planned, prepared, and presented webinar on inhibitor prevention and eradication in hemophilia. organized by NHF.	
Sangamo	Research Funding	Research funding for clinical trial	
Shire Development LL	Consultancy		01/01/2035
Shire Development LL	Research Funding	Shire is providing rVWF (Vonvendi) for my NIH-funded clinical trial in women with VWD.	
SPARK (formerly Children's Hospital of Philadelphia)	Consultancy	Advisory Board on gene therapy data, trials, and future practice	01/01/2034

Conflict of Interest Disclosures Blood Advances

SPARK (formerly Children's Hospital of Philadelphia)	Research Funding	AAV-2 IX Gene Trial in Hemophilia B, co-investigator AAV-8 FIX Gene trial in Hemophilia B, co-investigator AAV-8 VIII Gene trial in Hemophilia A, co-investigator	01/01/2034
Tacere Benitec	Membership on a Board or Advisory Committee		01/01/2035
Tacere Benitec	Membership on a Board or Advisory Committee	I serve on a DSMB for a Tacere hepatitis C study.	01/01/2035
Tacere Benitec	Membership on a Board or Advisory Committee	I serve on the DSMB for a hepatitis C clinical trial.	
Tacere Benitec	Research Funding		
Thrombosis Haemostasis Society of North America	Honoraria	THSNA Symposia Plenary Session: Targeting siRNA-AT3: Novel Therapeutic for Hemophilia" Chicago IL, April 14, 2016.	01/01/2036
Vascular Medicine Institute	Membership on a Board or Advisory Committee	Vascular Medicine Institute, Scientific Advisory Board, University of Pittsburgh, member 2009 -)	
Vascular Medicine Institute	Research Funding	Thrombin Generation in ITI Inhibitor Tolerance Study (PI) Anticoagulation in Acute Chest Syndrome (Mentor) rtPA Prevention of Central Line Thrombosis in Small Bowel Disease	

00000125050	Wendy Stock, MD	Associate Editor	Last Confirmed Date:
Company:	Relationship:	Additional Information	End Date
Amgen			
Genzyme	Research Funding	Research Funding	
Seattle Genetics	Membership on a Board or Advisory Committee		01/01/2036

Conflict of Interest Disclosures Blood Advances

00001009344	Andrew S. Weyrich, PhD	Associate Editor	Last Confirmed Date: 01/08/2018
--------------------	-------------------------------	-------------------------	--

Company:	Relationship:	Additional Information	End Date
	Nothing to disclose.		